By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
What an expert on the gut microbiome eats in a day - 2Tesla Germany Registrations Quadruple to 9,252 Vehicles in Best March Ever
- 3West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- 4Vote In favor of Your Favored Kind Of Cheddar
- 5Germany records first wolf bite on human since repopulation
- Amateur's Manual for Venture Strategies for Tenderfoots
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- Vote In favor of Your Favored Kind Of Bites
- Figure out How to Store Your Gold Ventures: A Thorough Aide safely
- Avoid Slam: Exploring the Pickup Truck Transformation
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
- Israel approves 19 new West Bank settlements in major annexation push
